Company intelligence / Profile preview

Ren Bioscience

King of Prussia, Pennsylvania, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Early studies demonstrate promise in protecting critical retinal cells, preventing irreversible vision loss across multiple inherited retinal diseases[1]. The company's lead compound has potential to make sight-saving treatment as simple as taking a pill[1].

Therapeutic areas: ImmunologyOphthalmologyNeurology
Modalities: Small molecules (pill-based therapy)
Industry: Biotech

Drug pipeline

1 asset

REN-101

Pre-clinical

Indications: Retinitis Pigmentosa, Stargardt Disease

Beyond the preview

Go deeper on Ren Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ren Bioscience.

Explore the full profile